LALL
MCID: LYM138
MIFTS: 50

Lymphoblastic Leukemia, Acute, with Lymphomatous Features (LALL)

Categories: Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards integrated aliases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

Name: Lymphoblastic Leukemia, Acute, with Lymphomatous Features 57 28 5
Acute Lymphoblastic Leukemia with Lymphomatous Features 71
Leukemia, Acute Lymphoblastic 57
Lymphomatous All 57
Lall 57

Characteristics:


Inheritance:

Acquired specific neoplasm by autosomal recessive mechanism through somatic cell mutation 57

Classifications:



External Ids:

OMIM® 57 247640
MedGen 40 C1855472
UMLS 71 C1855472

Summaries for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards based summary: Lymphoblastic Leukemia, Acute, with Lymphomatous Features, also known as acute lymphoblastic leukemia with lymphomatous features, is related to leukemia, acute lymphoblastic and leukemia. An important gene associated with Lymphoblastic Leukemia, Acute, with Lymphomatous Features is CRLF2 (Cytokine Receptor Like Factor 2), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Levoleucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include myeloid, spleen and t cells, and related phenotypes are lymphoma and t-cell acute lymphoblastic leukemias

More information from OMIM: 247640

Related Diseases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 31.1 JAK3 JAK2 JAK1 IL7R CRLF2 ABL1
2 leukemia 29.9 JAK2 FGFR1 CRLF2 ABL1
3 myeloid leukemia 29.6 JAK2 FGFR1 ABL1
4 leukemia, acute myeloid 28.1 JAK3 JAK2 JAK1 INSL6 IL7R FGFR1
5 leukemia, acute lymphoblastic 3 11.7
6 leukemia, acute lymphoblastic 2 11.6
7 t-cell acute lymphoblastic leukemia 11.3
8 thrombocythemia 3 10.1 JAK2 INSL6
9 b-lymphoblastic leukemia/lymphoma with bcr-abl1 10.1 CRLF2 ABL1
10 b-lymphoblastic leukemia/lymphoma with iamp21 10.1 CRLF2 ABL1
11 testicular leukemia 10.1 CRLF2 ABL1
12 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.1 JAK2 ABL1
13 stress polycythemia 10.1 JAK2 ABL1
14 myelophthisic anemia 10.1 JAK2 ABL1
15 precursor t-cell acute lymphoblastic leukemia 10.1
16 acquired polycythemia 10.1 JAK2 ABL1
17 erythrocytosis, familial, 1 10.1 JAK2 INSL6
18 chronic neutrophilic leukemia 10.0 JAK2 ABL1
19 splenomegaly 10.0 JAK2 INSL6
20 myelodysplastic/myeloproliferative neoplasm 10.0 JAK2 ABL1
21 aggressive systemic mastocytosis 10.0 JAK2 ABL1
22 cardiomyopathy, familial hypertrophic, 1 9.9
23 hypertrophic cardiomyopathy 9.9
24 coccidioidomycosis 9.9
25 cystoisosporiasis 9.9
26 coccidiosis 9.9
27 nutritional deficiency disease 9.9
28 systemic mastocytosis 9.9 JAK2 FGFR1
29 adult acute lymphocytic leukemia 9.9 CRLF2 ABL1
30 burkitt lymphoma 9.9
31 lymphoma 9.9
32 lymphoblastic lymphoma 9.9
33 acute leukemia 9.9
34 acute myeloblastic leukemia without maturation 9.9
35 acute myeloid leukemia with recurrent genetic anomaly 9.9
36 wernicke encephalopathy 9.9 JAK2 JAK1
37 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 9.8 JAK2 FGFR1 ABL1
38 atypical chronic myeloid leukemia, bcr-abl1 negative 9.8 JAK2 FGFR1 ABL1
39 chronic eosinophilic leukemia 9.8 JAK2 FGFR1 ABL1
40 chronic leukemia 9.8 JAK2 FGFR1 ABL1
41 juvenile myelomonocytic leukemia 9.8 JAK3 JAK2 ABL1
42 alopecia universalis congenita 9.8 JAK3 JAK1
43 rasopathy 9.8 JAK2 FGFR1 ABL1
44 gastrointestinal stromal tumor 9.8 JAK2 FGFR1 ABL1
45 nasopharyngitis 9.8 JAK3 JAK1
46 t-cell prolymphocytic leukemia 9.7 JAK3 JAK1
47 bone marrow cancer 9.7 JAK2 JAK1 ABL1
48 immunodeficiency 35 9.7 JAK3 JAK2 JAK1
49 blood platelet disease 9.6 JAK2 JAK1 ABL1
50 bare lymphocyte syndrome, type ii 9.6 JAK3 IL7R

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:



Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Symptoms & Phenotypes for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Human phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphoma 30 HP:0002665
2 t-cell acute lymphoblastic leukemias 30 HP:0006727

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Heme:
acute lymphoblastic leukemia (all)
lymphomatous all (lall)
t-cell all

Lab:
chromosome loss of bands 9p22-p21 by deletion, unbalanced translocation, or loss of entire chromosome
loss of methylthioadenosine phosphorylase in malignant cells during relapse

Misc:
bulky disease of lymph nodes, spleen, and mediastinum

Clinical features from OMIM®:

247640 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

25 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.93 ABL1 FGFR1
2 Decreased viability GR00221-A-2 9.93 ABL1 FGFR1 JAK1 JAK2
3 Decreased viability GR00221-A-3 9.93 ABL1
4 Decreased viability GR00249-S 9.93 JAK1
5 Decreased viability GR00342-S-1 9.93 ABL1
6 Decreased viability GR00342-S-2 9.93 ABL1
7 Decreased viability GR00342-S-3 9.93 ABL1
8 Decreased viability GR00386-A-1 9.93 FGFR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 FGFR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.78 JAK3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.78 IL7R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.78 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.78 IL7R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.78 IL7R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.78 JAK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.78 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.78 IL7R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.78 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.78 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.78 IL7R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.78 IL7R
23 Increased shRNA abundance (Z-score > 2) GR00366-A-20 9.78 JAK3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.78 ABL1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.78 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.78 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.78 ABL1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 ABL1 FGFR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 ABL1 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.78 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.78 JAK3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.78 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 ABL1 JAK3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.78 JAK3
35 Decreased viability in HMC1.1 cells GR00105-A-0 9.26 JAK1 JAK3
36 Increased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 8.96 ABL1 JAK1

MGI Mouse Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK1
2 cellular MP:0005384 9.7 ABL1 CRLF2 FGFR1 IL7R INSL6 JAK2
3 immune system MP:0005387 9.5 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2
4 hematopoietic system MP:0005397 9.17 ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2

Drugs & Therapeutics for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Drugs for Lymphoblastic Leukemia, Acute, with Lymphomatous Features (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Daunorubicin Approved Phase 3 20830-81-3 30323
5
Blinatumomab Approved, Investigational Phase 3 853426-35-4
6
Inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Tioguanine Approved Phase 3 154-42-7 2723601
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13
Palifosfamide Investigational Phase 3 31645-39-3 100427
14 Folic Acid Antagonists Phase 3
15 Folate Phase 3
16 Vitamin B9 Phase 3
17 Immunoglobulins Phase 3
18 Vitamin B Complex Phase 3
19 Antibodies, Bispecific Phase 3
20 Antibodies Phase 3
21 Dermatologic Agents Phase 3
22 Protein Kinase Inhibitors Phase 3
23 Anti-Bacterial Agents Phase 3
24 Antineoplastic Agents, Hormonal Phase 3
25 Hormones Phase 3
26 Antimitotic Agents Phase 3
27 Hormone Antagonists Phase 3
28 Antiemetics Phase 3
29 Tubulin Modulators Phase 3
30 glucocorticoids Phase 3
31 Anti-Inflammatory Agents Phase 3
32 Antibiotics, Antitubercular Phase 3
33 Liposomal doxorubicin Phase 3
34
Imatinib Mesylate Phase 3 220127-57-1
35 Gastrointestinal Agents Phase 3
36 Antineoplastic Agents, Immunological Phase 3
37
Busulfan Approved, Investigational Phase 2 55-98-1 2478
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
39
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
40
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
41
Ponatinib Approved, Investigational Phase 2 943319-70-8 24826799
42
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
43
Etoposide Approved Phase 2 33419-42-0 36462
44
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
45 Bendamustine Hydrochloride Phase 2
46 Anti-Infective Agents Phase 2
47 Calcineurin Inhibitors Phase 2
48 Antitubercular Agents Phase 2
49 OTS167 Phase 1, Phase 2
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL Completed NCT02393859 Phase 3 Blinatumomab;Dexamethasone;Vincrisitne;Daunorubicin;Methotrexate;Ifosfamide;PEG-asparaginase;Erwinia-asparaginase
2 ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) Recruiting NCT04307576 Phase 3 Omitted Doxorubicin;Omitted Vincristine+Dexamethasone pulses;Inotuzumab Ozogamicin+Standard Maintenance Therapy;Imatinib;6-tioguanine+Standard Maintenance Therapy;Blinatumomab
3 Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor Completed NCT01865617 Phase 1, Phase 2
4 Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia Completed NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
5 Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Recruiting NCT04942730 Phase 2 Fludarabine;Bendamustine Hydrochloride;Busulfan;Cyclophosphamide;Mycophenolate Mofetil;Tacrolimus 5Mg Cap
6 Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) Recruiting NCT05306301 Phase 2 Ponatinib
7 Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated NCT02795520 Phase 1, Phase 2 OTS167IV
8 BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study Terminated NCT01685606 Phase 2
9 Bridging Study: A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia and Minimal Residual Disease Terminated NCT02349178 Phase 2 Clofarabine;Cyclophosphamide;Etoposide
10 Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia Terminated NCT02935543 Phase 2
11 A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia Completed NCT00964873 Phase 1 STA-9090 (ganetespib)
12 Pilot Study of Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Leukemia Completed NCT04327037 Phase 1 IL-2
13 An Open Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults With Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia Recruiting NCT04872478 Phase 1 MRX-2843
14 The Pharmacokinetics and Pharmacodynamics of Vincristine in the Adolescent and Young Adult Population Compared to Younger Children Unknown status NCT02360930
15 Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy Recruiting NCT05064787
16 Effect of Fish Oil Versus Placebo on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia - A Randomized Controlled Trial Recruiting NCT04209244
17 A Treatment Study Protocol of the ALLTogether Consortium for Infants, Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study Recruiting NCT03911128
18 CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL Active, not recruiting NCT05440409
19 Erwinase Master Treatment Protocol No longer available NCT00590915 Erwinia L-asparaginase
20 Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses Suspended NCT02580981
21 iCare for Cancer Patients Terminated NCT02435550
22 Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center Terminated NCT01761682

Search NIH Clinical Center for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic Tests for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic tests related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

# Genetic test Affiliating Genes
1 Lymphoblastic Leukemia, Acute, with Lymphomatous Features 28

Anatomical Context for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Organs/tissues related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

MalaCards : Myeloid, Spleen, T Cells, Bone Marrow, Bone, Heart, Neutrophil

Publications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Articles related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

(show top 50) (show all 202)
# Title Authors PMID Year
1
Lymphomatous ALL with abnormalities of the short arm of chromosome 9. 62 57
3865054 1985
2
Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. 62 57
3925340 1985
3
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
4
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
5
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. 5
22772060 2013
6
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. 5
22955920 2012
7
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. 5
22897847 2012
8
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 5
22368270 2012
9
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. 5
22368272 2012
10
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. 5
20372971 2011
11
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. 5
21680795 2011
12
ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. 5
20167706 2010
13
Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. 5
19907440 2010
14
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. 5
19965641 2010
15
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. 5
20018760 2010
16
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 5
19838194 2009
17
JAK mutations in high-risk childhood acute lymphoblastic leukemia. 5
19470474 2009
18
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. 5
19139102 2009
19
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. 5
18805579 2008
20
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. 5
18615627 2008
21
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. 5
11861307 2002
22
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. 5
11853795 2002
23
Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. 57
6785752 1981
24
Literature Commentary. 62
36394969 2022
25
More people survived a cardiac arrest when first aiders received an app alert. 62
36368720 2022
26
Phytochemical Composition and Biological Activities of Angelica sylvestris L. var. stenoptera Avé-Lall ex Boiss.: An Endangered Medicinal Plant of Northeast Turkey. 62
36085404 2022
27
Intestinal parasites of buffalo calves from Romania: molecular characterisation of Cryptosporidium spp. and Giardia duodenalis, and the first report of Eimeria bareillyi. 62
35993791 2022
28
Verification of the folkloric and anecdotal antidiabetic effects of Hypoxis hemerocallidea (Fisch., C.A. Mey. & Avé-Lall) and isolated, β-sitosterol using early-stage type II spontaneous diabetic mutant BKS-Leprdb mice. 62
35725532 2022
29
Angelica purpurascens (Avé-Lall.) Gilli. Essential Oil Improved Brain Function via Cholinergic Modulation and Antioxidant Effects in the Scopolamine-Induced Zebrafish (Danio rerio) Model. 62
35448824 2022
30
A lifespan approach to understanding family caregiver experiences of a blood cancer diagnosis. 62
33890563 2022
31
[Research Progress of Intercellular Mitochondrial Transfer in the Development of Hematological Malignant Tumors --Review]. 62
35123645 2022
32
[Radiation-induced hematopoietic disorders]. 62
36198562 2022
33
Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. 62
34587551 2022
34
Structural Changes in Resin-Based Composites in Saliva of Patients with Leukemia before Starting Chemotherapeutic Regimen. 62
35160558 2022
35
[The Effect of Immunized Platelet Transfusion Refractoriness on Allo-HSCT Patients with Malignant Hematological Diseases]. 62
34893135 2021
36
Correction: Lall, S.P.; Kaushik, S.J. Nutrition and Metabolism of Minerals in Fish. Animals 2021, 11, 2711. 62
34944386 2021
37
Identifying carbohydrate-active enzymes of Cutaneotrichosporon oleaginosus using systems biology. 62
34711240 2021
38
LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies. 62
34082072 2021
39
Of mice and men: What a mouse model of microglial C9ORF72 deficiency does-and does not-tell us about human neurodegenerative diseases. 62
34293287 2021
40
Intraoperative Classification System Yields Favorable Outcomes for Patients Treated Surgically for Greater Trochanteric Pain Syndrome. 62
33581305 2021
41
Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. 62
33420393 2021
42
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria. 62
31688621 2021
43
Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma. 62
33563316 2021
44
Safety evaluation of the food enzyme maltogenic α-amylase from the genetically modified Saccharomyces cerevisiae strain LALL-MA. 62
33659030 2021
45
Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment. 62
35116045 2021
46
Phenolic compounds, essential oil composition, and antioxidant activity of Angelica purpurascens (Avé-Lall.) Gill. 62
34385879 2021
47
Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis. 62
33009604 2020
48
Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. 62
32976349 2020
49
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. 62
32619037 2020
50
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. 62
32434056 2020

Variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

ClinVar genetic disease variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

5 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 JAK2, INSL6 NM_004972.4(JAK2):c.2049A>C (p.Arg683Ser) SNV Pathogenic
375953 rs1057519723 GRCh37: 9:5078362-5078362
GRCh38: 9:5078362-5078362
2 JAK2, INSL6 NM_004972.4(JAK2):c.2047A>G (p.Arg683Gly) SNV Pathogenic
375951 rs1057519721 GRCh37: 9:5078360-5078360
GRCh38: 9:5078360-5078360
3 JAK2, INSL6 NM_004972.4(JAK2):c.2049A>T (p.Arg683Ser) SNV Pathogenic
375954 rs1057519723 GRCh37: 9:5078362-5078362
GRCh38: 9:5078362-5078362
4 JAK2, INSL6 NM_004972.4(JAK2):c.2048G>C (p.Arg683Thr) SNV Pathogenic
375952 rs1057519722 GRCh37: 9:5078361-5078361
GRCh38: 9:5078361-5078361
5 CRLF2 NM_022148.4(CRLF2):c.695T>G (p.Phe232Cys) SNV Pathogenic
376003 rs1057519743 GRCh37: Y:1264966-1264966
GRCh38: X:1196852-1196852
6 JAK3 NM_000215.4(JAK3):c.2164G>A (p.Val722Ile) SNV Likely Pathogenic
134573 rs3213409 GRCh37: 19:17945696-17945696
GRCh38: 19:17834887-17834887
7 FGFR1 NM_023110.3(FGFR1):c.1968G>C (p.Lys656Asn) SNV Likely Pathogenic
376428 rs1057519897 GRCh37: 8:38272306-38272306
GRCh38: 8:38414788-38414788
8 JAK1 NM_002227.4(JAK1):c.1937C>T (p.Ser646Phe) SNV Likely Pathogenic
376099 rs151047872 GRCh37: 1:65312382-65312382
GRCh38: 1:64846699-64846699
9 ABL1 NM_005157.6(ABL1):c.944C>T (p.Thr315Ile) SNV Likely Pathogenic
12624 rs121913459 GRCh37: 9:133748283-133748283
GRCh38: 9:130872896-130872896
10 JAK1 NM_002227.4(JAK1):c.1901C>A (p.Ala634Asp) SNV Likely Pathogenic
225075 rs869312953 GRCh37: 1:65312418-65312418
GRCh38: 1:64846735-64846735
11 JAK1 NM_002227.4(JAK1):c.1972G>T (p.Val658Phe) SNV Likely Pathogenic
376030 rs1057519753 GRCh37: 1:65312347-65312347
GRCh38: 1:64846664-64846664
12 JAK3 NM_000215.4(JAK3):c.394C>A (p.Pro132Thr) SNV Likely Pathogenic
134580 rs3212723 GRCh37: 19:17954215-17954215
GRCh38: 19:17843406-17843406
13 FGFR1 NM_023110.3(FGFR1):c.1966A>G (p.Lys656Glu) SNV Likely Pathogenic
224897 rs869320694 GRCh37: 8:38272308-38272308
GRCh38: 8:38414790-38414790
14 ABL1 NM_005157.6(ABL1):c.757T>C (p.Tyr253His) SNV Likely Pathogenic
12627 rs121913461 GRCh37: 9:133738357-133738357
GRCh38: 9:130862970-130862970
15 IL7R NM_002185.5(IL7R):c.553A>T (p.Ser185Cys) SNV Likely Pathogenic
376098 rs1057519759 GRCh37: 5:35873597-35873597
GRCh38: 5:35873495-35873495
16 NT5C2 NM_001351169.2(NT5C2):c.1075A>C (p.Lys359Gln) SNV Not Provided
376350 rs1057519867 GRCh37: 10:104852980-104852980
GRCh38: 10:103093223-103093223

Expression for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search GEO for disease gene expression data for Lymphoblastic Leukemia, Acute, with Lymphomatous Features.

Pathways for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Pathways related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 JAK3 JAK2 JAK1 IL7R FGFR1 ABL1
2
Show member pathways
13.29 JAK3 JAK2 JAK1 IL7R FGFR1
3
Show member pathways
13.22 ABL1 FGFR1 JAK1 JAK2 JAK3
4
Show member pathways
13.16 JAK3 JAK2 JAK1 IL7R FGFR1
5
Show member pathways
13.05 JAK3 JAK2 JAK1 IL7R CRLF2
6
Show member pathways
12.62 JAK3 JAK2 JAK1 FGFR1
7
Show member pathways
12.62 IL7R JAK1 JAK2 JAK3
8
Show member pathways
12.61 JAK3 JAK2 JAK1 IL7R FGFR1
9 12.36 JAK3 JAK2 JAK1
10
Show member pathways
12.19 JAK3 JAK2 JAK1
11
Show member pathways
12.14 JAK3 JAK2 JAK1 IL7R FGFR1 ABL1
12
Show member pathways
12.07 JAK3 JAK2 JAK1
13
Show member pathways
12.05 FGFR1 JAK1 JAK2 JAK3
14
Show member pathways
12 JAK1 IL7R FGFR1
15
Show member pathways
11.96 JAK3 JAK2 JAK1
16 11.9 JAK2 FGFR1 ABL1
17 11.75 JAK3 JAK2 JAK1
18 11.7 JAK3 JAK2 JAK1
19
Show member pathways
11.65 JAK3 JAK2 JAK1
20
Show member pathways
11.63 JAK3 JAK2 JAK1
21 11.45 JAK3 JAK2 JAK1
22 11.44 JAK2 JAK1
23
Show member pathways
11.41 JAK2 JAK1
25 11.39 JAK3 JAK2 JAK1
26
Show member pathways
11.35 JAK2 JAK1
27 11.32 JAK2 ABL1
28
Show member pathways
11.3 JAK3 JAK1
29 11.3 JAK2 JAK1
30 11.29 JAK2 JAK1
31 11.28 JAK3 JAK2 JAK1
32 11.2 JAK2 JAK1
33 11.11 JAK2 JAK1
34 10.93 JAK2 JAK1
35 10.92 JAK3 JAK2 JAK1 CRLF2
36 10.9 JAK3 JAK2 JAK1
37 10.69 JAK3 JAK2 JAK1
38 10.48 JAK3 JAK1 IL7R CRLF2

GO Terms for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Cellular components related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endomembrane system GO:0012505 8.8 JAK3 JAK2 JAK1

Biological processes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 10.19 ABL1 FGFR1 JAK1 JAK2 JAK3
2 positive regulation of cell population proliferation GO:0008284 10.15 JAK2 IL7R FGFR1 CRLF2
3 protein autophosphorylation GO:0046777 10.06 JAK2 FGFR1 ABL1
4 positive regulation of cytosolic calcium ion concentration GO:0007204 10.05 JAK3 JAK2 ABL1
5 response to antibiotic GO:0046677 9.89 JAK2 JAK1
6 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.87 JAK2 JAK3
7 negative regulation of cell-cell adhesion GO:0022408 9.86 JAK2 ABL1
8 interleukin-6-mediated signaling pathway GO:0070102 9.85 JAK2 JAK1
9 receptor signaling pathway via JAK-STAT GO:0007259 9.85 JAK3 JAK2 JAK1
10 type II interferon-mediated signaling pathway GO:0060333 9.84 JAK2 JAK1
11 regulation of receptor signaling pathway via JAK-STAT GO:0046425 9.83 JAK3 JAK2
12 enzyme-linked receptor protein signaling pathway GO:0007167 9.81 JAK3 JAK2
13 platelet-derived growth factor receptor signaling pathway GO:0048008 9.77 JAK2 ABL1
14 regulation of cell adhesion GO:0030155 9.76 JAK2 JAK1 ABL1
15 positive regulation of receptor signaling pathway via STAT GO:1904894 9.73 IL7R CRLF2
16 tyrosine phosphorylation of STAT protein GO:0007260 9.73 JAK1 JAK2 JAK3
17 phosphorylation GO:0016310 9.72 JAK3 JAK2 JAK1 FGFR1 ABL1
18 interleukin-2-mediated signaling pathway GO:0038110 9.71 JAK3 JAK1
19 cytokine-mediated signaling pathway GO:0019221 9.65 JAK3 JAK2 JAK1 IL7R CRLF2
20 growth hormone receptor signaling pathway via JAK-STAT GO:0060397 9.63 JAK3 JAK2 JAK1
21 regulation of multicellular organismal process GO:0051239 9.48 JAK2 JAK1
22 peptidyl-tyrosine phosphorylation GO:0018108 9.28 JAK3 JAK2 JAK1 FGFR1 ABL1

Molecular functions related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.87 JAK3 JAK2 JAK1 FGFR1 ABL1
2 kinase activity GO:0016301 9.85 JAK3 JAK2 JAK1 FGFR1 ABL1
3 nucleotide binding GO:0000166 9.83 JAK3 JAK2 JAK1 FGFR1 ABL1
4 transferase activity GO:0016740 9.8 JAK3 JAK2 JAK1 FGFR1 ABL1
5 cytokine receptor binding GO:0005126 9.73 JAK1 JAK2 JAK3
6 growth hormone receptor binding GO:0005131 9.63 JAK3 JAK2 JAK1
7 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.56 JAK3 JAK2 JAK1 ABL1
8 protein tyrosine kinase activity GO:0004713 9.32 JAK3 JAK2 JAK1 FGFR1 ABL1

Sources for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....